Nicolas Morgan, Partner, DLA Piper to Speak at KCs Event on Revenue Recognition for Biotech Firms on 7/29/2009
Summary
Under these arrangements, the companies agree to share technology and research costs associated with bringing medical therapies to market and this gives them access to additional funding and commercialization networks.Additionally, Mr. Morgan served as a Special Assistant US Attorney for the Southern District of California, obtaining indictments against the principals of a $330 million subprime mortgage lending scheme.“We bring together the worlds leading authorities and industry participants through informative two-hour Live webcast to study the impact of changing regulations.” To contact or to register for an event, please visit: www.knowledgecongress.org.Under these arrangements, the companies agree to share technology and research costs associated with bringing medical therapies to market and this gives them access to additional funding and commercialization networks.Mr. Morgan also advises clients in non-litigation settings, such as counseling public companies, funds and broker-dealer firms in securities compliance and corporate governance issues, conducting internal investigations and assisting in regulatory examinations by the SECs Division of Corporation Finance and Office of Compliance Inspections and Examinations.For more than seven years, from 1998 to 2005, Mr. Morgan prosecuted securities fraud in the SEC’s Enforcement Division, rising from staff attorney to branch chief to senior trial counsel.